Skip to main content
Top
Published in: Neurosurgical Review 1/2016

01-01-2016 | Original Article

Glioblastoma multiforme in the very elderly

Authors: Felicity V. Connon, Mark A. Rosenthal, Katherine Drummond

Published in: Neurosurgical Review | Issue 1/2016

Login to get access

Abstract

Glioblastoma is the most malignant and most common primary brain tumour and is treated with resection followed by post-operative radiotherapy and chemotherapy. However, a significant amount of patients are older than 80 years, and such an approach may not be appropriate. Data on patients aged 80 or older with glioblastoma from two hospitals was collected using the CNS Tumour Database on the Australian Comprehensive Cancer Outcomes and Research Database (ACCORD) system operated by BioGrid. Between 2008 and July 2011, 40 patients aged 80 years or older were diagnosed with glioblastoma. The median ECOG PS was 2 and the ASA score was 3. All 40 patients underwent surgery and 33 % had a gross total resection. Only six patients (15 %) had either post-operative radiotherapy or chemotherapy. The overall median survival was 4 months (range 0–18 months) and 28 % of patients lived between 6 and 24 months. This is the largest reported cohort of very elderly patients with glioblastoma. Patients tolerated surgery but few went on to receive post-operative radiotherapy or chemotherapy. This patient population requires special attention and in particular would benefit from participation in suitable clinical trials to determine the best care regime.
Literature
1.
go back to reference Chaichana KL, Chaichana KK, Olivi A et al (2011) Surgical outcomes for older patients with glioblastoma multiforme: pre-operative factors associated with decreased survival. J Neurosurg 114:587–594PubMedPubMedCentralCrossRef Chaichana KL, Chaichana KK, Olivi A et al (2011) Surgical outcomes for older patients with glioblastoma multiforme: pre-operative factors associated with decreased survival. J Neurosurg 114:587–594PubMedPubMedCentralCrossRef
2.
go back to reference Nghiemphu P, Cloughesy T (2012) Glioblastoma therapy in the elderly: one age does not fit all. Lancet Oncol 13(9):857–858PubMedCrossRef Nghiemphu P, Cloughesy T (2012) Glioblastoma therapy in the elderly: one age does not fit all. Lancet Oncol 13(9):857–858PubMedCrossRef
3.
go back to reference Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. NEJM 356:1527–1535PubMedCrossRef Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. NEJM 356:1527–1535PubMedCrossRef
4.
go back to reference Minitti G, Muni R, Lanzetta G et al (2009) Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res 29(12):5171–5184 Minitti G, Muni R, Lanzetta G et al (2009) Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res 29(12):5171–5184
5.
go back to reference Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase II study: 5 year analysis of the EORTC-NCIC trial. Lancet 10:459–466PubMedCrossRef Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase II study: 5 year analysis of the EORTC-NCIC trial. Lancet 10:459–466PubMedCrossRef
6.
go back to reference Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 352(10):987–996PubMedCrossRef Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM 352(10):987–996PubMedCrossRef
7.
go back to reference Laperriere N, O’Callaghan C, Ding K et al (2008) Rationale and design for a phase III randomized controlled trial in elderly patients with glioblastoma multiforme: NCIC CTG CE Canadian Neuro-oncology Annual Scientific Meeting Laperriere N, O’Callaghan C, Ding K et al (2008) Rationale and design for a phase III randomized controlled trial in elderly patients with glioblastoma multiforme: NCIC CTG CE Canadian Neuro-oncology Annual Scientific Meeting
8.
go back to reference Scott JG, Suh JH, Elson P et al (2011) Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years or older: a retrospective review of 206 cases. Neuro-Oncology 13(4):428–436PubMedPubMedCentralCrossRef Scott JG, Suh JH, Elson P et al (2011) Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years or older: a retrospective review of 206 cases. Neuro-Oncology 13(4):428–436PubMedPubMedCentralCrossRef
9.
10.
go back to reference Brandes A, Vastola F, Basso U et al (2003) A prospective study of glioblastoma in the elderly. Cancer 97(3):657–662PubMedCrossRef Brandes A, Vastola F, Basso U et al (2003) A prospective study of glioblastoma in the elderly. Cancer 97(3):657–662PubMedCrossRef
11.
go back to reference Iwamoto FM, Reiner A, Panageas KS, Elkin EB, Abrey LE (2008) Patterns of care in elderly glioblastoma. Ann Neurol 64:628–634PubMedCrossRef Iwamoto FM, Reiner A, Panageas KS, Elkin EB, Abrey LE (2008) Patterns of care in elderly glioblastoma. Ann Neurol 64:628–634PubMedCrossRef
12.
go back to reference Kita D, Ciernik F, Vaccarella S et al (2009) Age as a predictive factor in glioblastomas: population based study. Neuroepidemiology 33:17–22PubMedCrossRef Kita D, Ciernik F, Vaccarella S et al (2009) Age as a predictive factor in glioblastomas: population based study. Neuroepidemiology 33:17–22PubMedCrossRef
13.
go back to reference Bauchet L, Zouaoui S, Darlix A et al (2014) Assessment and treatment relevance in elderly glioblastoma patients. Neuro-Oncol 16: 1459−1468 Bauchet L, Zouaoui S, Darlix A et al (2014) Assessment and treatment relevance in elderly glioblastoma patients. Neuro-Oncol 16: 1459−1468
15.
go back to reference Reifenberger G, Hentschel B, Felsberg J et al (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131(6):1342–1350PubMedCrossRef Reifenberger G, Hentschel B, Felsberg J et al (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131(6):1342–1350PubMedCrossRef
16.
go back to reference Cancer Council Australia/Australian Cancer Network/Clinical Oncological Society of Australia Inc. (2009) Clinical practice guidelines for the treatment of adult gliomas: astrocytomas and oligodendromas Cancer Council Australia/Australian Cancer Network/Clinical Oncological Society of Australia Inc. (2009) Clinical practice guidelines for the treatment of adult gliomas: astrocytomas and oligodendromas
17.
go back to reference Scott JG, Bauchet L, Fraum TJ et al (2012) Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer 118(22):5595–5600PubMedPubMedCentralCrossRef Scott JG, Bauchet L, Fraum TJ et al (2012) Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer 118(22):5595–5600PubMedPubMedCentralCrossRef
18.
go back to reference Malmstrom A, Gronbberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926PubMedCrossRef Malmstrom A, Gronbberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 13:916–926PubMedCrossRef
19.
go back to reference Wick W, Platten M, Mmeisnner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomized, phase 3 trial. Lancet Oncol 13:707–715PubMedCrossRef Wick W, Platten M, Mmeisnner C et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomized, phase 3 trial. Lancet Oncol 13:707–715PubMedCrossRef
20.
go back to reference Paszat L, Laperriere N, Groome et al (2001) A population based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:100–107PubMedCrossRef Paszat L, Laperriere N, Groome et al (2001) A population based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:100–107PubMedCrossRef
21.
go back to reference Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wildtype anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas and IDH1 mutation status accounts for the unfavourable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718PubMedCrossRef Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wildtype anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas and IDH1 mutation status accounts for the unfavourable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718PubMedCrossRef
Metadata
Title
Glioblastoma multiforme in the very elderly
Authors
Felicity V. Connon
Mark A. Rosenthal
Katherine Drummond
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Neurosurgical Review / Issue 1/2016
Print ISSN: 0344-5607
Electronic ISSN: 1437-2320
DOI
https://doi.org/10.1007/s10143-015-0652-0

Other articles of this Issue 1/2016

Neurosurgical Review 1/2016 Go to the issue